Drug Trial Radar · NCT06200207
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
673
Planned (sponsor's estimate)
Start
Apr 1, 2024
Primary completion
Oct 1, 2026
Study completion Jan 8, 2027
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Conditions
- Heart Failure
- Systemic Inflammation
Interventions
ZiltivekimabDrug
Zilitivekimab will be administered subcutaneously once-monthly.
PlaceboDrug
Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)Time frame: From randomisation (month 0) to end-of-treatment (month 12)
Locations
217 sites in 16 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular, LLC
Alexander City, Alabama
Eastern Shore Rsrch Inst, LLC
Fairhope, Alabama
Cardiology & Medicine Clinic
Little Rock, Arkansas
Valley Clinical Trials, Inc.
Northridge, California
UCI Health
Orange, California
South California Heart Spc
Pasadena, California
Clearwater Cardiovascular Consultants
Largo, Florida
Ocala Cardiovascular Research
Ocala, Florida
Ormond Beach Clinical Research
Ormond Beach, Florida
St Johns Ctr Clin Rsch-St. Aug
Saint Augustine, Florida
GA Arrhythmia Cons & Rsch Inst
Macon, Georgia
Velocity Clin Rsrch - Savannah
Savannah, Georgia
Chicago Medical Research LLC
Hazel Crest, Illinois
UofL Health Care Outpatient
Louisville, Kentucky
Maryland Cardiovascular Specialists - Baltimore
Baltimore, Maryland
MD Medical Research
Oxon Hill, Maryland
Cardio and Vascular Assoc-CAVA
Bloomfield Hills, Michigan
Millennium Cardiology
Farmington Hills, Michigan
Kansas City VA Medical Center
Kansas City, Missouri
Washington University
St Louis, Missouri
Renown Regional Medical Center
Reno, Nevada
Long Island Cardiovascular Consultants PC
Lake Success, New York
Mount Sinai Hosp at NYC
New York, New York
Northwell Health Phys Cardio
Riverhead, New York
University Of North Carolina At Chapel Hill
Chapel Hill, North Carolina
AMS Cardiology
Horsham, Pennsylvania
Univ of Pennsylvania Hospital
Philadelphia, Pennsylvania
PharmaTex Research
Amarillo, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
David Turbay, MD, PLLC
El Paso, Texas
Private Practice Leadership LLC.
Katy, Texas
Clinical Advancement Center
San Antonio, Texas
Clinical Advancement Ctr, PLLC
San Antonio, Texas
Sherman Clinical Research
Sherman, Texas
Northwest Heart Center
Tomball, Texas
Sentara Health Research Center
Norfolk, Virginia
Virginia Commonwealth University
Richmond, Virginia
Instituto de Investigaciones Clinicas Quilmes SRL
Buenos Aires, Argentina
CIPREC Pueyrredon
Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
Buenos Aires, Argentina
Showing 40 of 217 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.